AbstractBackgroundLocalized scleroderma, known as morphea, is a connective tissue disorder characterized by inflammation and fibrosis of the skin and the soft tissue. There exist no universally accepted validated outcome measures in order to monitor the disease activity. Besides clinical scores to evaluate outcome measures, imaging modalities are increasingly utilized in assessing patients with morphea, such as high‐frequency ultrasonography (US), shear‐wave elastography (SWE), and magnetic resonance imaging (MRI). However, the accuracy of these imaging modalities in monitoring morphea activity is not yet clear.AimsTo review the literature regarding the role of imaging modalities in assessing patients with morphea.Materials & MethodsIn this study, we searched the PubMed/Medline database for articles published from inception until February 2023.ResultsA total number of 23 original articles in three categories of US, elastography, and MRI were included.DiscussionRegarding US, criteria, including increased dermal thickness, increased echogenicity of the subcutaneous tissue, and decreased dermal echogenicity, were indicators of active morphea lesions when using high frequencies probe (18–20 MHz) color Doppler sonography. Moreover, studies evaluating SWE, a novel method to quantitatively assess tissue stiffness, demonstrated increased dermal stiffness in active lesions.ConclusionStudies showed that MRI can help to determine the depth of disease, particularly as a first‐line and follow‐up diagnostic tool, especially in generalized and deep morphea. In addition, brain MRI may be useful for patients with localized craniofacial scleroderma experiencing new or worsening neurological symptoms.